Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868269 | 1.00 | SOAT1 (0.40) | SOAT1ALDH1A1OPRD1CHRM2CHRM1 | |
| SCHEMBL4877162 | 0.87 | SIGMAR1 (0.52) | CHRM2CHRM1CHRM3SIGMAR1KMT2A | |
| SCHEMBL4877150 | 0.87 | SIGMAR1 (0.52) | CHRM2CHRM1CHRM3SIGMAR1KMT2A | |
| SCHEMBL4880411 | 0.81 | ALDH1A1 (0.44) | SOAT1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4880406 | 0.81 | ALDH1A1 (0.44) | SOAT1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4876769 | 0.80 | ALDH1A1 (0.42) | SOAT1ALDH1A1OPRD1MEN1KMT2A | |
| SCHEMBL4876775 | 0.80 | ALDH1A1 (0.42) | SOAT1ALDH1A1OPRD1MEN1KMT2A | |
| SCHEMBL4872809 | 0.79 | SOAT1 (0.47) | SOAT1ALDH1A1CHRM1CHRM3MEN1 | |
| SCHEMBL4872820 | 0.79 | SOAT1 (0.47) | SOAT1ALDH1A1CHRM1CHRM3MEN1 | |
| SCHEMBL4878196 | 0.78 | MMP1 (0.42) | SOAT1ALDH1A1NPY1RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | SOAT1 502/4885ALDH1A1 2899/4885OPRD1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.